Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 22.57
XON's Cash to Debt is ranked lower than
52% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. XON: 22.57 )
Ranked among companies with meaningful Cash to Debt only.
XON' s Cash to Debt Range Over the Past 10 Years
Min: 9.17  Med: 82.44 Max: N/A
Current: 22.57
Equity to Asset 0.73
XON's Equity to Asset is ranked higher than
56% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. XON: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
XON' s Equity to Asset Range Over the Past 10 Years
Min: -2.12  Med: 0.70 Max: 0.8
Current: 0.73
-2.12
0.8
F-Score: 5
Z-Score: 7.09
M-Score: -1.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -80.53
XON's Operating margin (%) is ranked lower than
52% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. XON: -80.53 )
Ranked among companies with meaningful Operating margin (%) only.
XON' s Operating margin (%) Range Over the Past 10 Years
Min: -1008.77  Med: -394.92 Max: -97.26
Current: -80.53
-1008.77
-97.26
Net-margin (%) -20.19
XON's Net-margin (%) is ranked higher than
61% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. XON: -20.19 )
Ranked among companies with meaningful Net-margin (%) only.
XON' s Net-margin (%) Range Over the Past 10 Years
Min: -1043.69  Med: -379.24 Max: -113.75
Current: -20.19
-1043.69
-113.75
ROE (%) -6.39
XON's ROE (%) is ranked higher than
70% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. XON: -6.39 )
Ranked among companies with meaningful ROE (%) only.
XON' s ROE (%) Range Over the Past 10 Years
Min: -254.03  Med: -137.91 Max: -21.78
Current: -6.39
-254.03
-21.78
ROA (%) -4.43
XON's ROA (%) is ranked higher than
72% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. XON: -4.43 )
Ranked among companies with meaningful ROA (%) only.
XON' s ROA (%) Range Over the Past 10 Years
Min: -61.45  Med: -15.65 Max: -12.55
Current: -4.43
-61.45
-12.55
ROC (Joel Greenblatt) (%) -53.42
XON's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. XON: -53.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XON' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -872.72  Med: -243.33 Max: -230.87
Current: -53.42
-872.72
-230.87
» XON's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

XON Guru Trades in Q4 2014

T Boone Pickens 10,000 sh (New)
Daniel Loeb 2,900,000 sh (unchged)
David Einhorn Sold Out
First Eagle Investment 789,864 sh (-0.06%)
» More
Q1 2015

XON Guru Trades in Q1 2015

Chase Coleman 300,000 sh (New)
T Boone Pickens 17,500 sh (+75.00%)
First Eagle Investment 828,104 sh (+4.84%)
Daniel Loeb 2,700,000 sh (-6.90%)
» More
Q2 2015

XON Guru Trades in Q2 2015

First Eagle Investment 872,604 sh (+5.37%)
T Boone Pickens 17,500 sh (unchged)
Daniel Loeb 2,700,000 sh (unchged)
Chase Coleman Sold Out
» More
Q3 2015

XON Guru Trades in Q3 2015

First Eagle Investment 1,009,689 sh (+15.71%)
T Boone Pickens Sold Out
Daniel Loeb 1,500,000 sh (-44.44%)
» More
» Details

Insider Trades

Latest Guru Trades with XON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Intrexon Corp

CEO and Part Owner of JMP Group Invests in Company Joseph Jolson acquires 87,532 company shares
Joseph Jolson (Insider Trades), CEO and 10% owner of JMP Group LLC (JMP), bought 87,532 shares in the company on Jan. 19. Read more...

Ratios

vs
industry
vs
history
P/B 5.08
XON's P/B is ranked lower than
85% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. XON: 5.08 )
Ranked among companies with meaningful P/B only.
XON' s P/B Range Over the Past 10 Years
Min: 3.58  Med: 6.14 Max: 15.07
Current: 5.08
3.58
15.07
P/S 20.46
XON's P/S is ranked lower than
73% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. XON: 20.46 )
Ranked among companies with meaningful P/S only.
XON' s P/S Range Over the Past 10 Years
Min: 5.94  Med: 33.96 Max: 67.47
Current: 20.46
5.94
67.47
POCF 283.54
XON's POCF is ranked lower than
92% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 25.75 vs. XON: 283.54 )
Ranked among companies with meaningful POCF only.
XON' s POCF Range Over the Past 10 Years
Min: 233.36  Med: 300.64 Max: 453.73
Current: 283.54
233.36
453.73
Current Ratio 3.92
XON's Current Ratio is ranked lower than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. XON: 3.92 )
Ranked among companies with meaningful Current Ratio only.
XON' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 4.76 Max: 10.49
Current: 3.92
0.81
10.49
Quick Ratio 3.63
XON's Quick Ratio is ranked lower than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. XON: 3.63 )
Ranked among companies with meaningful Quick Ratio only.
XON' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 4.28 Max: 10.49
Current: 3.63
0.81
10.49
Days Inventory 139.80
XON's Days Inventory is ranked lower than
55% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. XON: 139.80 )
Ranked among companies with meaningful Days Inventory only.
XON' s Days Inventory Range Over the Past 10 Years
Min: 244.37  Med: 244.37 Max: 244.37
Current: 139.8
Days Sales Outstanding 56.26
XON's Days Sales Outstanding is ranked higher than
58% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. XON: 56.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
XON' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.89  Med: 7.94 Max: 73.99
Current: 56.26
0.89
73.99
Days Payable 26.93
XON's Days Payable is ranked lower than
73% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. XON: 26.93 )
Ranked among companies with meaningful Days Payable only.
XON' s Days Payable Range Over the Past 10 Years
Min: 118.77  Med: 8827.68 Max: 17536.59
Current: 26.93
118.77
17536.59

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 119.96
XON's Price/Net Current Asset Value is ranked lower than
98% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 5.14 vs. XON: 119.96 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
XON' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 20.21  Med: 59.31 Max: 1791
Current: 119.96
20.21
1791
Price/Tangible Book 12.28
XON's Price/Tangible Book is ranked lower than
83% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 3.93 vs. XON: 12.28 )
Ranked among companies with meaningful Price/Tangible Book only.
XON' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.9  Med: 9.43 Max: 27.73
Current: 12.28
6.9
27.73
Price/Median PS Value 0.61
XON's Price/Median PS Value is ranked higher than
67% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: 0.89 vs. XON: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
XON' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.07 Max: 1.85
Current: 0.61
0.21
1.85
Earnings Yield (Greenblatt) (%) -1.08
XON's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. XON: -1.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XON' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.6  Med: 0.00 Max: 0
Current: -1.08
-3.6
0

More Statistics

Revenue(Mil) $163
EPS $ -0.27
Short Percentage of Float41.05%
52-Week Range $18.52 - 69.45
Shares Outstanding(Mil)116.40

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:I5X.Germany,
Intrexon Corp was founded in 1998. The Company designs, builds and regulates gene programs and cellular systems to enable the development of new and improved products and processes across a variety of market sectors, including Health, Food, Energy and Environment.The Company operates in one segment. It uses synthetic biology for the creation of distinct products developed in collaboration with partners. All of the Company's revenues are derived in the United States of America and all of its assets are located in the United States of America. The Company is subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials and the health and safety of employees with respect to laboratory activities required for the development of products and technologies.
» More Articles for XON

Headlines

Articles On GuruFocus.com
CEO and Part Owner of JMP Group Invests in Company Jan 20 2016 
Intrexon Corp is expanding his business Jun 25 2015 
Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

More From Other Websites
U.S. Steel, Tesla And Four Other Hot Stocks Among Short-Selling Circles Feb 10 2016
These Two Companies Are Working On The Zika Virus Cure Feb 09 2016
2 Longs and 2 Shorts to Watch in this Volatile Market Feb 09 2016
Zika On Wall Street: Can These Companies Really Cash In On The Virus? Feb 09 2016
AmpliPhi Biosciences Announces Award of Federal Research Grant from Australia to its Collaboration... Feb 09 2016
ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral... Feb 09 2016
3 Biotech Stocks to Turn the Tide This Earnings Season Feb 08 2016
Smart Science: Wolbachia Bacteria Might Stop Zika and Dengue Viruses Feb 05 2016
Cerus Corp. May Have Treatment For Zika Virus Feb 04 2016
4 Bullish Charts to Watch for Momentum Feb 04 2016
Most Searched Tickers Among Financial Advisors: Focus on Tech Following Earnings Feb 04 2016
Bill MIller's 'genius' play on synthetic biology Feb 03 2016
Synthetic Biologics to Present at the 2016 BIO CEO & Investor Conference Feb 03 2016
Intrexon Corp. – Value Analysis (NYSE:XON) : February 2, 2016 Feb 02 2016
Intrexon Corp. breached its 50 day moving average in a Bullish Manner : February 2, 2016 Feb 02 2016
ZIOPHARM to Present at the 18th Annual BIO CEO & Investor Conference Feb 02 2016
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from... Feb 02 2016
Here’s Why Intrexon (XON) Stock is Jumping Today Feb 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK